Qartemi: India’s First Internationally Licensed CAR-T Therapy for B-NHL

Recently, India witnessed the launch of Qartemi, the country’s first internationally licensed CAR-T cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL). This groundbreaking therapy offers new hope for patients suffering from aggressive blood cancers.

What is CAR-T Therapy?

CAR-T therapy is a type of immunotherapy.

It involves modifying a patient’s T-cells to better target and eliminate cancer cells.

The process includes collecting T-cells, genetically modifying them, and reinfusing them into the patient.

This approach is known as a living drug.

Clinical Trials and Efficacy

The IMAGINE trial tested Qartemi in multiple hospitals, including Narayana Hospital and Apollo Cancer Hospital. The Phase 2 trial reported an overall response rate (ORR) of 83.3%, indicating a strong efficacy compared to global standards.

Impact on Blood Cancer in India

India faces a rising burden of blood cancers, with approximately 120,000 new cases annually. Qartemi aims to address this issue by providing an effective treatment option for patients with relapsed or refractory B-NHL.

Future of Cancer Treatment

The launch of Qartemi is seen as a transformative step in personalised medicine. It combines advanced research with indigenous manufacturing, aiming to redefine cancer treatment standards in India.

What is Non-Hodgkin Lymphoma (NHL)?

It is a type of cancer that affects the lymphatic system, which is part of the immune system.

The lymphatic system includes organs, glands, vessels, and lymph nodes that help fight germs.

NHL occurs when germ-fighting lymphatic cells grow uncontrollably, forming tumors in various parts of the body.

NHL is a broad group of lymphomas with many subtypes.

Common subtypes:

Diffuse Large B-cell Lymphoma (DLBCL)

Follicular Lymphoma

NHL is distinct from Hodgkin Lymphoma, the other main type of lymphoma.